Royal Bank of Canada
ZNTL icon

Royal Bank of Canada’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Royal Bank of Canada’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
98
-12,642
-99% -$32.6K ﹤0.01% 7767
2025
Q4 		$17K Buy
12,740
+12,318
+2,919% +$17.9K ﹤0.01% 6153
2025
Q3 		$1K Sell
422
-2,019
-83% -$3.03K ﹤0.01% 7041
2025
Q2 		$2K Sell
2,441
-3,864
-61% -$5.1K ﹤0.01% 6827
2025
Q1 		$10K Sell
6,305
-20,606
-77% -$44.4K ﹤0.01% 6170
2024
Q4 		$82K Buy
26,911
+20,066
+293% +$65.8K ﹤0.01% 5452
2024
Q3 		$25K Buy
6,845
+945
+16% +$3.44K ﹤0.01% 6031
2024
Q2 		$24K Buy
5,900
+3,018
+105% +$33.7K ﹤0.01% 6004
2024
Q1 		$46K Sell
2,882
-14,645
-84% -$201K ﹤0.01% 5579
2023
Q4 		$266K Buy
17,527
+9,878
+129% +$144K ﹤0.01% 4852
2023
Q3 		$154K Buy
7,649
+4,353
+132% +$110K ﹤0.01% 5037
2023
Q2 		$93K Buy
3,296
+615
+23% +$14.8K ﹤0.01% 5399
2023
Q1 		$46K Sell
2,681
-5,249
-66% -$106K ﹤0.01% 5671
2022
Q4 		$161K Buy
7,930
+7,333
+1,228% +$158K ﹤0.01% 5069
2022
Q3 		$13K Sell
597
-13,956
-96% -$382K ﹤0.01% 6316
2022
Q2 		$409K Sell
14,553
-1,993
-12% -$52.8K ﹤0.01% 4255
2022
Q1 		$763K Sell
16,546
-6,347
-28% -$342K ﹤0.01% 3899
2021
Q4 		$1.92M Buy
22,893
+19,439
+563% +$1.5M ﹤0.01% 3190
2021
Q3 		$230K Buy
3,454
+1,178
+52% +$68K ﹤0.01% 5050
2021
Q2 		$121K Sell
2,276
-89
-4% -$4.77K ﹤0.01% 5479
2021
Q1 		$103K Buy
2,365
+1,697
+254% +$73.1K ﹤0.01% 5443
2020
Q4 		$35K Buy
668
+642
+2,469% +$29K ﹤0.01% 5810
2020
Q3 		$1K Buy
26
+4
+18% +$140 ﹤0.01% 6494
2020
Q2 		$1K Buy
+22
New +$844 ﹤0.01% 6495

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Royal Bank of Canada's ZNTL Position: Q1 2026 in Review

Royal Bank of Canada reduced its Zentalis Pharmaceuticals (ZNTL) stake by 99% in Q1 2026, selling an estimated $32.6K and leaving 98 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7767.

Royal Bank of Canada first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.92M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Royal Bank of Canada held 98 shares of Zentalis Pharmaceuticals worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 12,642 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $32.6K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7767 holding.
  • Royal Bank of Canada first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Royal Bank of Canada's Zentalis Pharmaceuticals position peaked at $1.92M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.